Berdeja JG et al. A phase 1 study of CFT7455, a novel degrader of IKZF1/3, in multiple myeloma and non-Hodgkin lymphoma. ASH 2021;Abstract 1675.

Henderson JA et al. The discovery and characterization of CFT7455: A potent and selective degrader of IKZF1/3 for the treatment of relapsed/refractory multiple myeloma. AACR 2022;Abstract ND13.

Lonial S et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed/refractory multiple myeloma. Lancet Hematol 2022;9(11):e822-32. Abstract

Lonial S et al. Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM. AACR 2022;Abstract CT186.

Lonial S et al. Iberdomide (iber) in combination with dexamethasone (dex) and daratumumab (dara), bortezomib (bort), or carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). EHA 2021;Abstract S187.

Richardson PG et al. Mezigdomide (CC-92480), a potent, novel cereblon E3 ligase modulator (CELMoD), combined with dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Preliminary results from the dose-expansion phase of the CC-92480-MM-001 trial. ASH 2022;Abstract 568.

Richardson PG et al. Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (dex) and bortezomib (bort) or carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk 2022;22(suppl 1):S33. Abstract

Richardson PG et al. First-in-human phase 1 study of the novel CELMoD agent CC-92480 combined with dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). ASCO 2020;Abstract 8500.